Tenax Thera tanks on Phase III trial miss for TNX-103 in PH-HFpEF
Tenax Therapeutics (Nasdaq: TENX) shares fell about 90% to $1.38 after it reported Phase III LEVEL trial top-line results for TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not meet the primary endpoint of improving 6-minute walk distance versus placebo, nor a key secondary endpoint on Kansas City Cardiomyopathy Questionnaire symptom score, according to the company.
How this was made
The 30-second read
Why it matters
The company reported that LEVEL did not meet its primary endpoint (6-minute walk distance vs placebo) and did not meet a key secondary endpoint (Kansas City Cardiomyopathy Questionnaire total symptom score), triggering a sharp selloff.
Market read
This is a direct late-stage clinical de-risking event for TENX, with immediate implications for valuation and trading liquidity.
What to watch
The article does not mention safety/tolerability, effect size direction, or whether the trial was underpowered, which could moderate the long-term narrative if later disclosed.
Background
Tenax Therapeutics is evaluating TNX-103 (oral levosimendan) in a Phase III LEVEL trial for pulmonary hypertension with preserved ejection fraction (PH-HFpEF).
Ticker impact
Tenax Therapeutics shares fell about 90% after Phase III LEVEL trial results for TNX-103 missed the 6-minute walk primary endpoint and a key symptom secondary endpoint.
Further downside risk and elevated volatility are likely until the company clarifies next steps (resubmission, additional trials, or strategic alternatives).
The article reports a Phase III top-line failure against both primary and key secondary endpoints, which typically drives sharp de-risking for biotech programs.
Market effects
Reinforces high clinical-risk pricing for pulmonary hypertension and HFpEF drug development, potentially weighing on sentiment for similar late-stage programs.
Primarily impacts US small-cap biotech risk appetite.
Limited broader macro impact; mostly company-specific de-risking.
Counterpoint
A Phase III miss can still leave room for subgroup effects, protocol nuances, or alternative endpoints, so the selloff may over-discount if follow-up analyses are favorable.
Key entities
- companyTenax Therapeutics
Nasdaq-listed developer of TNX-103; reported Phase III LEVEL trial top-line misses.
- drugTNX-103
Oral levosimendan being tested in PH-HFpEF Phase III LEVEL trial.
- clinical_programLEVEL clinical trial
Phase III study in PH-HFpEF; missed primary and key secondary endpoints per the article.
